Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table At a glance Prototype drug / retatrutide (LY3437943) Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor agonism Phase 2 weight loss (48 wk) / 24.2% mean body weight reduction vs 2.1% placebo Primary metabolic targets / obesity, MASLD/MASH, T2D, dyslipidemia Gastric emptying effect / marked slowing, peak drug interaction risk 1 to 4 h post-dose Oral drug most affected / warfarin, oral contraceptives, levothyroxine, cyclosporine Hypoglycemia risk / low monotherapy
When combined, copper peptides show promise in improving many aspects of hair and skin health
By understanding the causes, prevention, and treatment options, users can take proactive steps to manage this side effect
Any claims about cognitive benefits in healthy humans are extrapolated from animal models without supporting clinical trial data
Whether its right for you depends on your goals, your health profile, and, most importantly, a qualified provider who can guide the process.